Rezvilutamide

Rezvilutamide (INN;[1][2] developmental code name SHR3680) is a nonsteroidal antiandrogen which is under development by Jiangsu Hengrui Medicine for the treatment of prostate cancer and breast cancer.[3][4] It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide.[3][4] As of October 2020, rezvilutamide is in phase 3 clinical trials for prostate cancer.[3] Other structural analogues of rezvilutamide besides enzalutamide include apalutamide and proxalutamide.

Rezvilutamide
Clinical data
Other namesSHR3680
Drug classNonsteroidal antiandrogen
Identifiers
IUPAC name
  • 4-[3-[4-[(2S)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC22H20F3N3O4S
Molar mass479.47 g·mol−1
3D model (JSmol)
SMILES
  • CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)OC[C@H](CO)O)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChI
  • InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1
  • Key:KRBMOYIWQCZVHA-INIZCTEOSA-N

See also

References
  1. "Rezvilutamide". chemidplus. U.S. National Library of Medicine.
  2. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO.
  3. "SHR 3680". AdisInsight.
  4. Qin X, Han W, Luo H, Du C, Zou Q, Sun Z, et al. (2020). "SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study". Journal of Clinical Oncology. 38 (6_suppl): 90. doi:10.1200/JCO.2020.38.6_suppl.90. S2CID 214027454.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.